VANCOUVER, BC -- (MARKET WIRE) -- September 26, 2006 -- Upstream Biosciences Inc. (OTCBB: UPBS) (“Upstream” or “the Company”), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, is pleased to announce that, on September 25, 2006 it filed a provisional patent application with the U.S. Patent and Trademark Office for certain thyroid cancer biomarkers that could be useful for determining whether patients have a genetic risk of developing thyroid cancer.
